We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
supports HTML5 video
Published byAiden Patton
Modified over 4 years ago
R&D Financing by the Bill & Melinda Gates FoundationPRESENTED BY Neil McDonnell, Pharm.D. January 12, 2009 WHO Expert Working Group on R&D Financing
Gates Foundation MissionTo ensure that life-saving advances in health are developed & shared with those who need them the most. (Photo, chart, or graph here) © 2009 Bill & Melinda Gates Foundation | ‹2›
How We Prioritize Our WorkGreatest burden The areas that cause widespread illness and death: infectious diseases, undernutrition, and reproductive maternal, neonatal, and child health Widest imbalance Problems that disproportionately affect poor countries Gaps in attention Fill in areas receiving inadequate attention and resources Benefit the most people Prevention has the greatest impact – focus on vaccines and other prevention strategies, micronutrient deficiencies Be willing to take risks Innovation requires accepting risks © 2009 Bill & Melinda Gates Foundation | ‹3›
DALYs by Cause, Low Income CountriesNon-Foundation Priorities: 43% Foundation Priorities: 57% © 2009 Bill & Melinda Gates Foundation | ‹4›
How We Prioritize Our WorkGreatest burden The areas that cause widespread illness and death: infectious diseases, undernutrition, and reproductive maternal, neonatal, and child health Widest imbalance Problems that disproportionately affect poor countries Gaps in attention Fill in areas receiving inadequate attention and resources Benefit the most people Prevention has the greatest impact – focus on vaccines and other prevention strategies, micronutrient deficiencies Be willing to take risks Innovation requires accepting risks © 2009 Bill & Melinda Gates Foundation | ‹5›
Foundation Support for Discovery, Development, and DeliveryGlobal Health Impact Appropriate Uptake and Use © 2009 Bill & Melinda Gates Foundation | ‹6›
Gates Foundation Support for Drugs and Vaccines in Late-Stage Preclinical or Clinical DevelopmentProduct Class Candidates HIV (Vaccines) 13 HIV (Non-Vaccine Prevention) 9 TB (Vaccines) 6 TB (drugs) 2 Malaria (vaccines) 10 Malaria (drugs) Pneumonia (vaccines) 5 Diarrhea (vaccines) 11 Diarrhea (drugs) 1 Dengue Fever Visceral Leishmaniasis 3 Human African Trypanosomiasis Hookworm Japanese Encephalitis Human Papillomavirus Product/Platform Candidates 4 Total 77 © 2009 Bill & Melinda Gates Foundation | ‹7›
Product Development Partnerships Supported by the Gates FoundationDiarrhea International Vaccine Institute Enteric Vaccine Initiative Advancing Rotavirus Vaccine Development HIV/AIDS International AIDS Vaccine Initiative International Partnership for Microbicides Malaria Medicines for Malaria Venture Malaria Vaccine Initiative NTD Dengue: Pediatric Dengue Vaccine Initiative Hookworm: Human Hookworm Vaccine Initiative Leishmaniasis: Infectious Disease Research Institute Trypanosomiasis: UNC Consortium for Parasitic Drug Development Multiple: Drugs for Neglected Diseases Initiative Respiratory Infection Influenza Vaccine Development Program Meningitis Vaccine Project Pneumococcal Vaccine Development Program TB Aeras Global TB Vaccine Foundation Global Alliance for TB Drug Development Cross-Cutting Foundation for Innovative New Diagnostics Innovative Vector Control Consortium Institute for One World Health © 2009 Bill & Melinda Gates Foundation | ‹8›
Global Health Program Payout© 2008 Bill & Melinda Gates Foundation
The Need for R&D in Global HealthGuaranteed obsolescence in infectious diseases We need for newer, better methods of prevention Many disease for which no effective treatment or prevention is available Innovation is required to meet these challenges Financing innovation requires a willingness to make extremely risky investments © 2008 Bill & Melinda Gates Foundation
Providing Access to Medicines and Vaccines for the Poor – Focus on R & DGovernments Support for basic research Support innovative finance mechanisms designed to stimulate R&D Support for funds such as the Global Fund, GAVI, UNITAID, etc. Industry Research, development, and manufacturing to addresses global disease burden and neglected diseases Access Plans © 2008 Bill & Melinda Gates Foundation
Providing Access to Medicines and Vaccines for the Poor – Focus on R & DFoundations Work in defined niches Support innovation and development of new health solutions Operating at the interface between governments, the private sector, and other interested parties De-risking subsequent investments by the public and private sectors © 2008 Bill & Melinda Gates Foundation
Many players to incentivize in R&D, final common pathway through industryPharma Biotech Govern-ment Lab Academic Lab Academic Lab ResearchInstitute ResearchInstitute Discovery Development Product Approval Introduction Govern-ment Lab Pharma Biotech Govern-ment Lab Biotech Company Pharma Biotech Company Pharma Pharma Biotech © 2008 Bill & Melinda Gates Foundation
Stimulating Global Health R&DWe need incentives for governments, foundations, and a broad cross section of industries to participate in the R&D effort We need to identify novel mechanisms to fund global health R&D and new policies that encourage more R&D. We have to be willing to take risks © 2008 Bill & Melinda Gates Foundation
Health Doing Business with the World - The new role of corporate leadership in global development Geneva, September 2007 World Business Council for Sustainable.
World Health Organization Information, Evidence and Research The Road to Bamako Tim Evans Assistant Director General, WHO Scaling Up Research and Learning.
1 Translation of Research Findings for Prevention and Control of NCDs Shanthi Mendis Chronic Disease Prevention and Management World Health Organization.
Research Leaders: Meeting the challenge Mark Walport 19 November 2008.
Story of an Essential Resolution The WHO Resolution on A Global Framework on Essential Health R&D.
Diseases without borders What must the Global Development Community Do? World Bank Seminar Series Tawhid Nawaz, Operations Advisor Human Development Network.
WHO Expert Working Group on R&D and Financing January 2009 G-FINDER: Global Funding of Innovation for Neglected Diseases.
© IFPMA 2009 IFPMA to WHO EWG 12 Jan 09 1 Alicia D. Greenidge, Director General, IFPMA WHO Expert Working Group, Geneva, 12 Jan 2009 IFPMA Presentation.
Global Alliance for Vaccines and Immunization. n An Alliance u Traditional and new partners u Public and private sector n Partners have in common: u Situation.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD A report prepared by WHO for the Netherlands Government by Warren Kaplan Richard Laing and Saloni TannaMarjolein.
What to include? Should EDCTP-2 be expanded to other fields? Marja Esveld, 29 September 2010.
The Effectiveness of Global Health Partnerships Findings and Lessons from a World Bank Evaluation of Global Health Programs Uma Lele April 14, 2005.
Health Economics. Outline Health Economics Do Health and Economics go well together? Health Economics: An interesting job Who is hiring health economists...
Consortium québécois sur la découverte du médicament Facilitating creative partnerships in biopharmaceutical research Ottawa, November 30 th, 2009 Diane.
Karin Weyer WHO Stop TB Department Stop TB Partnership Global Laboratory Initiative.
Trends in TB R&D investment: Where is funding most needed? Lindsey Wu Policy Analyst Policy Cures
Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.
WASH Cluster – Emergency Training D D1 1 WASH Related Diseases Session 1 The Environmental Burden of Disease.
DFID and the Health MDGs
Chapter Sixteen Science, Technology, and Global Health.
© 2018 SlidePlayer.com Inc. All rights reserved.